Inhibitors of neovascularization.
The use of neovascular inhibitors in the treatment of CNV will no doubt have a profound impact in the future. However, complex issues surround the use of these agents. Careful clinical trials will be necessary to determine the optimal parameters for their use. Furthermore, it must be determined whether these inhibitors will be most efficacious as primary agents or as agents used to augment the efficacy of photoreactive laser treatment or feeder vessel treatment.
York
J
J
Glaser Murphy Retina Treatment Center, 901 Dulaney Valley Road, Suite 200, Baltimore, MD 21204, USA.
Glaser
B
B
Murphy
R
R
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D006801:Humans; D008268:Macular Degeneration / Q000188:drug therapy* / Q000503:physiopathology*; D009389:Neovascularization, Pathologic / Q000503:physiopathology*
D020533:Angiogenesis Inhibitors